

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-6 (Cancelled)

7 (Currently amended): A substantially pure polypeptide comprising the amino acid sequence depicted in ~~Figure 8 (SEQ ID NO:3)~~ SEQ ID NO:1.

8 (Currently amended): A substantially pure polypeptide comprising the amino acid sequence depicted in ~~Figure 9 (SEQ ID NO:4)~~ SEQ ID NO:2.

9-18 (Cancelled)

19 (New): An isolated polypeptide encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule consisting of a nucleotide sequence that is the complement of SEQ ID NOs: 13, 14, 15, or 16 under highly stringent conditions and is functionally equivalent to a P-II polypeptide.

20 (New): The polypeptide of any one of claims 7, 8, or 19, which is recombinantly produced.

21 (New): The polypeptide of any one of claims 7, 8, or 19, which is produced by a chemical synthetic method.

22 (New): A fragment of the polypeptide of any one of claims 7, 8, or 19, wherein the fragment is functionally equivalent to said polypeptide. .

23 (New): A fusion polypeptide comprising the polypeptide of any one of claims 7, 8 or 19 and a heterologous polypeptide.

24 (New): The fusion polypeptide of claim 23, wherein the heteologous polypeptide is lac Z, β -galactosidase, GUS, or luciferase.

25 (New): The polypeptide of any one of claims 7 or 8, which further comprises one or more conservative amino acid substitutions in an amino acid sequence comprising the polypeptide.

26 (New): The polypeptide of any one of claim 19, which further comprises one or more conservative amino acid substitutions in an amino acid sequence comprising the polypeptide.

27 (New): An antibody which binds to the polypeptide of any one of claims 7, 8 or 19.

28 (New): The antibody of claim 26, which is monoclonal or polyclonal.

29 (New): An F(ab')₂ antibody fragment that binds to the polypeptide of any one of claims 7, 8 or 19.